Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Attend a group training Schedule a 1-on-1 guided demo Watch a demo video
WEBINAR ENDED

Lilly Sponsored Promotional Webinar

About This Webinar

Lilly Sponsored Promotional Webinar

PP-TR-GB-0267 March 2024 
12:30-13:30 and 19:00-20:00

Intended for Healthcare Professionals in Great Britain

This webinar has been developed, organised and funded by Lilly. The speaker(s) have been selected, briefed and paid an honorarium by Lilly. ABCD have promoted, registered attendees and hosted this webinar in collaboration with Lilly.

An Introduction to Mounjaro®▼ (tirzepatide) and the SURPASS-2 Data

Meeting objectives:
- Explain the proposed effects of incretins in the body
- Discuss the effects of Mounjaro® on HbA1c and weight vs semaglutide 1 mg in SURPASS-2
- Summarise the safety data from SURPASS-2

Mounjaro® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as a monotherapy when metformin is considered inappropriate due to intolerance or contradictions
- in addition to other medicinal products for the treatment of diabetes¹

References:
1. Mounjaro® Summary of Product Characteristics.

Prescribing information (hosted externally: https://www.lillydiabetes.co.uk/assets/pdf/mounjaro_digital_prescribing_information.pdf) Mounjaro®▼ (tirzepatide)

Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000

To learn more about Lilly, please visit us at www.lilly.co.uk

Mounjaro® and Lilly are registered trademarks of Eli Lilly and Company

© 2024 Eli Lilly and Company. All rights reserved

PP-TR-GB-0267 March 2024

Featured Presenters
Webinar hosting presenter

Dipesh Patel

Royal Free Hospital, London
Dr Dipesh C. Patel is a Consultant physician who is involved in the delivery of specialist clinical care in diabetes and general endocrinology and acute medicine at the Royal Free and Cleveland Clinic hospitals in London. His academic interests include cardiovascular disease in type 2 diabetes, he undertook work in cellular cholesterol transport leading to a PhD in 2010 at Imperial College. He has an interest in the use of newer diabetes therapies and clinical trials. He has undergraduate teaching lead and clinical trial responsibilities at the Royal Free campus and is an Honorary Clinical Associate Professor at UCL.

Dr Patel has had a number of specialist advisory roles for the NHS, Royal College of Physicians and is past chair of the UK National body of diabetes consultant and trainees- Association of British Clinical Diabetologists (ABCD).
VIEW PROFILE
Webinar hosting presenter

Professor Mike Cummings

Consultant in Diabetes and Endocrinology / Honorary Professor in Diabetes and Endocrinology
Professor Mike Cummings was appointed as Consultant in Diabetes and Endocrinology at Portsmouth NHS Trust in 1996. He is also Honorary Professor in Diabetes and Endocrinology at Portsmouth University. His major areas of interest in Diabetes are linked to cardiovascular disease and risks (in particular dyslipidaemia, dysglycaemia and microalbuminuria), diabetes and pregnancy and erectile dysfunction. He also has an interest in pancreatic exocrine insufficiency in diabetes. His endocrine interest links to thyroid lumps, endocrine fertility and hypogonadism. His research portfolio includes endothelial dysfunction, oxidative stress, dysglycaemia and lipid metabolism. He lectures widely on diabetes and lipid related topics and has published extensively within these areas. Professor Cummings is also Wessex Lead for Diabetes Research as part of the NIHR. He is Associate Editor of Practical Diabetes and Sub-Editor of Diabetes Digest
VIEW PROFILE
Recommended
Powered by BigMarker